Thank you for downloading the Analytical Tools to Evaluate CAR-T Cell Signaling & Activation App Note

CAR-T cell therapy has emerged as a powerful weapon in the fight against specific B-cell malignancies. Its success has fueled significant research efforts to broaden its reach to encompass a wider range of hematologic and solid tumors. 

 

Optimizing CAR-T cell therapy hinges on a deeper understanding of the intricate signaling pathways that govern these potent immune cells. This includes their ability to infiltrate tumors, evade antigen escape mechanisms, resist immunosuppression, and minimize potentially fatal toxicities. To achieve this, researchers require a comprehensive characterization of the signaling molecules involved, encompassing the extracellular, membrane-bound, and intracellular compartments. However, this endeavor is often hampered by limited and complex sample types. 

 

The Wilson Wolf G-Rex platform offers a unique solution for large-scale expansion of CAR-T cells, enabling researchers to study these vital communication networks within larger, more robust cell populations. This facilitates a deeper understanding of CAR-T cell function and paves the way for the development of safer and more effective CAR-T therapies. 

 

Unleash the Full Potential of CAR-T Cells: Learn More 

Understanding these vital communication networks within CAR-T cells is critical to unlocking their full potential. Download our free App Note: Analytical Tools to Evaluate CAR-T Cell Signaling & Activation to explore the latest advancements in research methods for optimizing CAR-T cell therapy. 

Latest Insights

Multiply Labs and Wilson Wolf Join Forces to Automate Cell Therapy Manufacturing with G-Rex® Bioreactors

Multiply Labs and Wilson Wolf are partnering to automate G-Rex® bioreactors for cheaper, more accessible cell therapy manufacturing. This partnership focuses on automating Wilson Wolf's innovative G-Rex® bioreactors, aiming to revolutionize CGT manufacturing.

Unlocking the Potential of Stem Cells: A New Frontier in Cancer Immunotherapy

Cancer immunotherapy has revolutionized treatment, but existing strategies have limitations. Natural Killer (NK) cells, part of our immune system, show amazing potential to destroy both blood and solid tumor cancers. However, getting enough consistently potent NK cells for therapy is tricky.

Innovating Cell Therapy Manufacturing: The Path to Decentralization and GMP Success

Cell therapies are exploding with potential, offering groundbreaking new treatments for a wide range of diseases. Yet, a central challenge lies in bringing these complex therapies out of the lab and into the real world. In a recent panel discussion, Josh Ludwig (Global Commercial Director, ScaleReady) and Stuart Curbishley (Chief Manufacturing & Development Officer, Adthera Bio) shed light on this complex transition.

Are you ready to scale?

Let’s talk more about how ScaleReady can advance your cell and gene therapy research and manufacturing with ingenious efficiency.